← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #553 OF 1,000 MOST-CITED

Air Supply

FDA cited this observation 33 times across 28 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs33
BY FISCAL YEAR
FY20251
FY20247
FY20234
FY20227
FY20211
FY20202
FY20196
FY20183
FY20172

How FDA worded it — real examples

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Nephron SC, LLC · West Columbia, South Carolina · Drugs · 2025-08-22

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Pine Pharmaceuticals, LLC · Tonawanda, New York · Drugs · 2024-09-30

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

OurPharma LLC · Fayetteville, Arkansas · Drugs · 2024-09-27

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Nephron SC, LLC · West Columbia, South Carolina · Drugs · 2024-09-25

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

AJENAT PHARMACEUTICALS LLC · Largo, Florida · Drugs · 2024-08-16

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

American Regent, Inc. · Shirley, New York · Drugs · 2024-04-24

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →